

Patient Information

First name _____ Last name _____
 Gender Male Female Date of birth (mm/dd/yy) _____
 Ancestry Caucasian Eastern European Northern European
 Western European Native American Middle Eastern
 African American Asian Pacific Islander
 Caribbean Central/South American
 Ashkenazi Jewish Hispanic Other: _____

Mailing address _____
 City _____ State _____ Zip code _____

Billing address Check if billing address is same as mailing address
 City _____ State _____ Zip code _____

Home phone _____ Work phone _____

Email _____ Patient's primary language if not English _____

Sample Information

Medical record # _____ Specimen ID _____ Date sample obtained (mm/dd/yy) _____

Blood in EDTA (5-6 mL in lavender top tube)
 DNA (>20 ug): Tissue source _____ concentration ____ (ug/ml) total Volume ____ (ul)
 Oral Rinse (At least 30 mL of Scope oral rinse in a 50 mL centrifuge tube)
 Buccal Swab
 Other _____ (Call lab)

Patient has had a blood transfusion Yes No Date of last transfusion __/__/__
 (2-4 weeks of wait time is required for some testing)

Fibroblasts are recommended for patients who had an allogenic bone marrow transplant. See www.genedx.com/specimen-requirements for details.
 Treatment-Related **RUSH**: _____ (If known, please provide date)

Clinical Diagnosis: _____ **ICD-10 Codes:** _____

Age at Initial Presentation: _____

Ordering Account Information

Acct # _____ Account Name _____
 Reporting Preference*: Care Evolve Fax Email
**If unmarked, we will use the account's default preferences or fax to new clients.*

Physician _____ NPI # _____
 Genetic Counselor _____
 Street address 1 _____
 Street address 2 _____
 City _____ Postal Code _____ Country _____
 Phone _____ Fax (important) _____
 Email _____ Beeper _____

Signature _____ Date (mm/dd/yy) _____

Send Additional Report Copies To:

Physician or GC/Acct # _____ Fax#/Email/CE # _____
 Physician or GC/Acct # _____ Fax#/Email/CE # _____

Institution Billing:

We are able to invoice institutions that are outside of the United States. Payment can be by check, credit card or wire transfer. \$30 wire transfer fee must be added to cost of test when paying by wire transfer. Payment must be in \$US Dollars.

Patient Pay: Samples from outside the United States must be accompanied by full payment at the time of sample submission when being paid by patient/family. Payment by check or credit card must be included with sample when patient is paying. If paying by wire transfer, payment must be received before sample arrives or shortly thereafter. A \$30 wire transfer fee must be added to cost of test when paying by wire transfer. Payment must be in \$US Dollars.

We Do Not Bill International Insurance Companies

Wire Transfer Information: GeneDx offers the convenience of payment by Automated Clearing House (ACH) Payment or Wire Transfer. If you would like to pay by ACH or Wire Transfer please add an additional handling fee of \$30 in US Funds.

For more information, please call +1 301 519 2100.

Payment Options

Billing Address

GeneDx Account # _____ Hospital/Lab Name _____ Contact Name _____
 Address 1 _____
 Address 2 _____ Postal Code _____ Country _____
 Phone _____ Fax _____ Email _____

Payment Information

Amount _____ Check Wire Transfer
 Credit Card (I understand that my credit card will be charged the full amount for the testing) Visa American Express Discover Mastercard

Name as it appears on card _____ Account Number _____ Expiration Date (mm/yy) _____ CVC _____
 Billing Address _____ Postal Code _____ Country _____
 Signature _____ Date: (mm/dd/yy) _____

For GeneDx Use Only

Account # _____ Account Name _____

First Name _____ Last Name _____ Date of Birth (mm/dd/yy) _____

Patient Clinical Information DETAILED MEDICAL RECORDS MUST BE ATTACHED

No Personal History of Cancer(s)/Tumor(s) or Pancreatitis

Clinical Diagnosis: _____ ICD-10 Codes: _____ Diagnosis Age(s): _____

Breast Cancer(s) Age(s) at Dx: _____ ER _____ PR _____ HER2 _____ triple negative
 Bilateral Two Primaries Invasive Ductal Invasive Lobular
 DCIS LCIS Other: _____

Ovarian Cancer(s) Age(s) at Dx: _____
 Serous Mucinous Endometrioid Clear Cell
 LMP/Borderline Other: _____

Endometrial Cancer(s) Age(s) at Dx: _____
 Serous Mucinous Endometrioid Clear Cell
 Sarcoma Other: _____

Pancreatic Cancer(s) Age(s) at Dx: _____
 Adenocarcinoma IPMN Neuroendocrine Other: _____

Pancreatitis Age(s) at Dx: _____
 Acute Chronic

Prostate Cancer Age at Dx: _____ Gleason Score: _____

Melanoma(s) Age(s) at Dx: _____ Invasive In-Situ

Hematologic Disease* Age(s) at Dx: _____ Diagnosis: _____
 Status: Active/Residual Disease Remission Allogenic bone marrow transplant

* Fibroblasts may be the preferred specimen; visit www.genedx.com/specimen-requirements

Colorectal Cancer(s) Age(s) at Dx: _____ Pathology: _____
 Location: Right Left Transverse Rectum

Polyp(s) Age of first polyp: _____ Adenomatous - total #: _____
 Other - Pathology: _____ Other - total #: _____

Gastric Cancer(s)/Tumor(s) Age(s) at Dx: _____ Pathology: _____

Endocrine Cancer(s)/Disease Age(s) at Dx: _____
 Thyroid Parathyroid Pituitary
 Pheochromocytoma (PCC) Paraganglioma (PGL) Location: _____
 Pathology/Diagnosis: _____

Renal Cancer(s)/Tumor(s) Age(s) at Dx: _____ Bilateral
 Clear Cell Papillary Type (I or II) : _____
 Transitional Cell Other: _____

Brain Cancer(s)/Tumor(s) Age(s) at Dx: _____ Pathology: _____

Other Cancer/Tumor _____ Age at Dx: _____

Comments: _____

Genetic Testing History

Please include copies of all previous genetic test results, tumor test results and detailed medical records.

For certain hematological conditions fibroblasts are the preferred specimen. More information can be found at www.genedx.com/specimen-requirements

Patient's Germline

No Personal History of Genetic Testing
 Prior Testing History Gene(s) Tested: _____
 Results: Negative Positive VUS
 Gene(s): _____
 c. _____
 p. _____

Previous Familial Genetic Testing

No Known Family History of Genetic Testing
 Relationship to Proband: _____
 Results: Negative Positive VUS
 Gene(s): _____
 c. _____
 p. _____

Patient's Tumor Testing History

No Known Tumor Testing
 Lynch Screening: Tumor Type: _____
 MSI: Not Done High Stable Low
 IHC: Not Done Present
 Absent IHC of: _____
 MLH1 Methylation: Not Done Methylated - Tumor Only
 Methylated - Tumor and Normal Tissue Unmethylated
 BRAF V600E: Not Done Present Absent
 Other: _____
 Other Tumor Testing: Tumor Type: _____
 Test Performed: _____
 Results: _____

Family History of Cancer(s)/Tumor(s) or Relevant History

No Known Family History

Pedigree Attached Adopted

Please include clinical details, such as bilateral, pathology (including triple negative breast cancer), premenopausal breast cancer, and Gleason score for prostate cancer. For pancreatitis history, please indicate acute or chronic, if available.

Relationship	Maternal	Paternal	Cancer/Tumor Site or Relevant History	Age at Dx
_____	<input type="checkbox"/>	<input type="checkbox"/>	_____	_____
_____	<input type="checkbox"/>	<input type="checkbox"/>	_____	_____
_____	<input type="checkbox"/>	<input type="checkbox"/>	_____	_____
_____	<input type="checkbox"/>	<input type="checkbox"/>	_____	_____
_____	<input type="checkbox"/>	<input type="checkbox"/>	_____	_____

Additional Patient or Family Clinical History

Account # _____ Account Name _____

First Name _____ Last Name _____ Date of Birth (mm/dd/yy) _____

OncoGeneDx - Test Menu

<p>Breast/Gynecologic Cancers</p> <p><input type="checkbox"/> B361 BRCA1/BRCA2 Ashkenazi Founder Panel¹ (Three Targeted Pathogenic Variants) <input type="checkbox"/> Reflex to test code: _____</p> <p><input type="checkbox"/> B362 BRCA1/BRCA2 Sequencing and Deletion/Duplication Analysis <input type="checkbox"/> Reflex to test code: _____</p> <p><input type="checkbox"/> J055 Breast Cancer Management Panel (9 genes)</p> <p><input type="checkbox"/> B273 Breast/Gyn Cancer Panel (23 genes)</p> <p>Colorectal Cancer</p> <p><input type="checkbox"/> B274 Colorectal Cancer Panel (20 genes)</p> <p><input type="checkbox"/> B522 Lynch/Colorectal High Risk Panel (7 genes)</p>	<p>Multiple Cancers</p> <p><input type="checkbox"/> B275 Comprehensive Common Cancer Panel (46 genes)</p> <p><input type="checkbox"/> B751 Common Cancer Management Panel (37 genes)</p> <p><input type="checkbox"/> B363 Rest of Comprehensive Common Cancer Panel (if first test is negative)¹</p> <p>Specialty Panels</p> <p><input type="checkbox"/> T830 Hereditary MDS/Leukemia Panel (10 genes)¹</p> <p><input type="checkbox"/> J899 Hereditary Pancreatitis Panel (5 genes)¹</p> <p><input type="checkbox"/> T828 Hyperparathyroidism/Endocrine Tumor Panel (11 genes)¹</p> <p><input type="checkbox"/> J318 Pediatric Tumor Panel (27 genes)¹</p>	<p>Tumor Specific Panels</p> <p><input type="checkbox"/> T831 Brain Tumor Panel (23 genes)¹</p> <p><input type="checkbox"/> J665 Hereditary Prostate Cancer Panel (16 genes)</p> <p><input type="checkbox"/> B399 Melanoma Panel (9 genes)</p> <p><input type="checkbox"/> B343 Pancreatic Cancer Panel (15 genes)</p> <p><input type="checkbox"/> B395 PGL/PCC Panel (12 genes)</p> <p><input type="checkbox"/> B394 Renal Cancer Panel (18 genes)</p>
--	---	---

¹Rest of Comprehensive Common Cancer Panel is not available after test codes B361, J318, J899, T830, T828 or T831.

B749 OncoGeneDx Custom Panel

Please select one or more genes to create a custom panel (no minimum). Up to 64 genes are available.

B749 OncoGeneDx Custom Panel - Include all genes from test code(s) _____ in addition to gene(s) selected below.

- | | | | | | | | | | | |
|--------------------------------|---------------------------------|---------------------------------|---------------------------------|--|----------------------------------|----------------------------------|--------------------------------------|---------------------------------|----------------------------------|-------------------------------|
| <input type="checkbox"/> ALK | <input type="checkbox"/> BMPR1A | <input type="checkbox"/> CDK4 | <input type="checkbox"/> FH | <input type="checkbox"/> MTF* ¹ | <input type="checkbox"/> NF1 | <input type="checkbox"/> POLD1 | <input type="checkbox"/> RAD51C | <input type="checkbox"/> SDHA* | <input type="checkbox"/> SMARCA4 | <input type="checkbox"/> TSC1 |
| <input type="checkbox"/> APC | <input type="checkbox"/> BRCA1 | <input type="checkbox"/> CDKN2A | <input type="checkbox"/> FLCN | <input type="checkbox"/> MLH1 | <input type="checkbox"/> NF2 | <input type="checkbox"/> POLE | <input type="checkbox"/> RAD51D | <input type="checkbox"/> SDHAF2 | <input type="checkbox"/> SMARCB1 | <input type="checkbox"/> TSC2 |
| <input type="checkbox"/> ATM | <input type="checkbox"/> BRCA2 | <input type="checkbox"/> CHEK2 | <input type="checkbox"/> HOXB13 | <input type="checkbox"/> MSH2 | <input type="checkbox"/> NTHL1 | <input type="checkbox"/> POT1 | <input type="checkbox"/> RB1 | <input type="checkbox"/> SDHB | <input type="checkbox"/> STK11 | <input type="checkbox"/> VHL |
| <input type="checkbox"/> AXIN2 | <input type="checkbox"/> BRIP1 | <input type="checkbox"/> DICER1 | <input type="checkbox"/> MAX | <input type="checkbox"/> MSH6 | <input type="checkbox"/> PALB2 | <input type="checkbox"/> PRKARIA | <input type="checkbox"/> RECQL | <input type="checkbox"/> SDHC | <input type="checkbox"/> SUFU | <input type="checkbox"/> WT1 |
| <input type="checkbox"/> BAP1 | <input type="checkbox"/> CDC73 | <input type="checkbox"/> EPCAM* | <input type="checkbox"/> MEN1 | <input type="checkbox"/> MUTYH | <input type="checkbox"/> PHOX2B* | <input type="checkbox"/> PTCH1 | <input type="checkbox"/> RET* | <input type="checkbox"/> SDHD | <input type="checkbox"/> TMEM127 | |
| <input type="checkbox"/> BARD1 | <input type="checkbox"/> CDHI | <input type="checkbox"/> FANCC | <input type="checkbox"/> MET | <input type="checkbox"/> NBN | <input type="checkbox"/> PMS2 | <input type="checkbox"/> PTEN | <input type="checkbox"/> SCGS/GREMI* | <input type="checkbox"/> SMAD4 | <input type="checkbox"/> TP53 | |

If OncoGeneDx Custom Panel is negative, reflex to test code: _____

Other Hereditary Cancers Test Menu

- | | |
|--|---|
| <input type="checkbox"/> 714 Birt-Hogg-Dube syndrome (FLCN) (Seq & Del/Dup) | <input type="checkbox"/> 718 Li-Fraumeni syndrome (TP53) (Seq & Del/Dup) |
| <input type="checkbox"/> 372 Bloom syndrome (BLM) (Seq) | <input type="checkbox"/> 719 Multiple endocrine neoplasia, type 1 (MEN1) (Seq & Del/Dup) |
| <input type="checkbox"/> 715 Carney complex (PRKARIA) (Seq & Del/Dup) | <input type="checkbox"/> 1771 Multiple endocrine neoplasia, types 2A and 2B (RET) (Seq) |
| <input type="checkbox"/> 205 Gorlin syndrome (PTCH1) (Seq & Del/Dup) | <input type="checkbox"/> 195 PTEN hamartoma tumor syndrome (PTEN) (Seq & Del/Dup) |
| <input type="checkbox"/> 713 Hereditary leiomyomatosis and renal cell cancer (FH) (Seq & Del/Dup) | <input type="checkbox"/> 2071 Peutz-Jeghers syndrome (STK11) (Seq & Del/Dup) |
| <input type="checkbox"/> TB50 Hereditary Retinoblastoma (RB1) (Seq & Del/Dup) | <input type="checkbox"/> 332 Von Hippel-Lindau syndrome (VHL) (Seq & Del/Dup) |
| <input type="checkbox"/> 721 Hyperparathyroidism-jaw tumor syndrome (CDC73) (Seq & Del/Dup) | <input type="checkbox"/> Other Test (include test code and name): _____ |
| <input type="checkbox"/> 717 Juvenile polyposis syndrome (BMPR1A, SMAD4) (Seq & Del/Dup) | |

Targeted Variant Testing

- B370 Testing for a previously identified variant**
- Gene: _____ Variant: _____
- Proband Name: _____ Relationship to proband: _____
- Proband GeneDx Accession #: _____
- Positive control included/will be sent - **Positive control is recommended if previous test was performed at another lab.**
- Positive control not available. Please initial to acknowledge acceptance of caveat language on a negative report _____
- Family Member Test Report included - A clear copy of the test report on the positive family member is recommended if previous test was performed at another lab.

Variant Testing Program (requires lab approval)

- B753 Previously identified variant of uncertain significance**
- VTP Family ID: **F** _____
- Gene(s): _____
- Variant(s): _____
- Proband Name: _____
- Relationship to proband: _____
- Proband GeneDx Accession #: _____

Account # _____ Account Name _____

First Name _____ Last Name _____ Date of Birth (mm/dd/yy) _____

OncoGeneDx Panel Components

Breast/Gynecologic Cancers

J055	Breast Cancer Management Panel (9 genes)	ATM, BRCA1, BRCA2, CDH1, CHEK2, NBN, PALB2, PTEN, TP53
B273	Breast/Gyn Cancer Panel (23 genes)	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM*, FANCC, MLH1, MSH2, MSH6, MUTYH, NBN, NFI, PALB2, PMS2, POLD1, PTEN, RAD51C, RAD51D, RECQL, TP53

Colorectal Cancers

B274	Colorectal Cancer Panel (20 genes)	APC, ATM, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM*, MLH1, MSH2, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SCG5/GREMI*, SMAD4, STK11, TP53
B522	Lynch/Colorectal High Risk Panel (7 genes)	APC, EPCAM*, MLH1, MSH2, MSH6, MUTYH, PMS2

Multiple Cancers

B275	Comprehensive Common Cancer Panel (46 genes)	APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM*, FANCC, FH, FLCN, HOXB13, MET, MTF*, MLH1, MSH2, MSH6, MUTYH, NBN, NFI, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTEN, RAD51C, RAD51D, RECQL, SCG5/GREMI*, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL
B751	Common Cancer Management Panel (37 genes)	APC, ATM, AXIN2, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM*, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, NBN, NFI, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SCG5/GREMI*, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL

Specialty Panels

T830	Hereditary MDS/Leukemia Panel (10 genes)	ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, SRP72, TERC, TERT, TP53
J899	Hereditary Pancreatitis Panel (5 genes)	CASR, CFTR, CTSC, PRSS1*, SPINK1
T828	Hyperparathyroidism/Endocrine Tumor Panel (11 genes)	AIP, APC, CASR, CDC73, CDKN1B, CHEK2, DICER1, MEN1, PRKARIA, PTEN, RET
J318	Pediatric Tumor Panel (27 genes)	ALK, APC, CDC73, DICER1, EPCAM*, MEN1, MLH1, MSH2, MSH6, NFI, NF2, PHOX2B*, PMS2, PRKARIA, PTCH1, PTEN, RBI, RET*, SMARCA4, SMARCB1, STK11, SUFU, TP53, TSC1, TSC2, VHL, WT1

Tumor Specific Panels

T831	Brain Tumor Panel (23 genes)	APC, CDKN1B, CDKN2A, DICER1, EPCAM, MEN1, MLH1, MSH2, MSH6, NFI, NF2, PMS2, POT1, PTCH1, PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL
J665	Hereditary Prostate Cancer Panel (16 genes)	ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM*, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53
B399	Melanoma Panel (9 genes)	BAP1, BRCA2, CDK4, CDKN2A, MITF*, POT1, PTEN, RBI, TP53
B343	Pancreatic Cancer Panel (15 genes)	APC, ATM, BRCA1, BRCA2, CDK4, CDKN2A, EPCAM*, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, VHL
B395	PGL/PCC Panel (12 genes)	FH, MAX, MEN1, NFI, RET*, SDHA*, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL
B394	Renal Cancer Panel (18 genes)	BAP1, EPCAM*, FH, FLCN, MET, MTF*, MLH1, MSH2, MSH6, PMS2, PTEN, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL

*Testing includes sequencing and deletion/duplication for all genes except EPCAM (del/dup only), MITF (evaluation of c.952G>A only), PHOX2B (seq only), PRSS1 (seq only), RET (seq only), SCG5/GREMI (del/dup only), SDHA (seq only).